- Home
- FLNT vs OTLK Comparison
FLNT vs OTLK Comparison
Compare FLNT & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNT
- OTLK
- Stock Information
- Founded
- FLNT 2010
- OTLK 2010
- Country
- FLNT United States
- OTLK United States
- Employees
- FLNT N/A
- OTLK N/A
- Industry
- FLNT Advertising
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLNT Consumer Discretionary
- OTLK Health Care
- Exchange
- FLNT Nasdaq
- OTLK Nasdaq
- Market Cap
- FLNT 58.9M
- OTLK 56.3M
- IPO Year
- FLNT N/A
- OTLK 2016
- Fundamental
- Price
- FLNT $2.81
- OTLK $1.56
- Analyst Decision
- FLNT Hold
- OTLK Strong Buy
- Analyst Count
- FLNT 1
- OTLK 5
- Target Price
- FLNT $4.00
- OTLK $12.00
- AVG Volume (30 Days)
- FLNT 6.4K
- OTLK 650.8K
- Earning Date
- FLNT 04-01-2025
- OTLK 02-14-2025
- Dividend Yield
- FLNT N/A
- OTLK N/A
- EPS Growth
- FLNT N/A
- OTLK N/A
- EPS
- FLNT N/A
- OTLK N/A
- Revenue
- FLNT $261,976,999.00
- OTLK N/A
- Revenue This Year
- FLNT N/A
- OTLK N/A
- Revenue Next Year
- FLNT $10.36
- OTLK $396.84
- P/E Ratio
- FLNT N/A
- OTLK N/A
- Revenue Growth
- FLNT N/A
- OTLK N/A
- 52 Week Low
- FLNT $2.31
- OTLK $0.87
- 52 Week High
- FLNT $4.30
- OTLK $12.85
- Technical
- Relative Strength Index (RSI)
- FLNT 45.52
- OTLK 34.22
- Support Level
- FLNT $2.87
- OTLK $1.58
- Resistance Level
- FLNT $3.05
- OTLK $1.99
- Average True Range (ATR)
- FLNT 0.16
- OTLK 0.15
- MACD
- FLNT -0.01
- OTLK -0.00
- Stochastic Oscillator
- FLNT 13.78
- OTLK 6.52
About FLNT Fluent Inc.
Fluent Inc is a data-driven digital marketing services company. It performs customer acquisition services by operating digital marketing campaigns, through which it connects its advertiser clients with consumers they are seeking to reach. It delivers data and performance-based marketing executions to its clients, such as consumer brands, direct marketers and agencies across a wide range of industries, including Financial Products & Services, Media & Entertainment, Health & Wellness, Staffing & Recruitment and Retail & Consumer.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.